Carolina Boza-Calvo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Carolina Boza-Calvo has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Anthony Q. Briggs
Department of Neurology, New York University Grossman School of Medicine, New York, New York, USA
3 shared publications - Arjun Vijay Masurkar
Department of Neurology, NYU Grossman School of Medicine, 145 East 32nd Street, New York, NY 10016, USA
3 shared publications - Mark Anthony Bernard
Department of Neurology, New York University Grossman School of Medicine, New York, New York, USA
3 shared publications Karyn Marsh
NYU Alzheimer’s Disease Research Center
2 shared publications- Alberto Rivelino Patiño Rivera
Facultad de Ingeniería, Universidad Nacional Intercultural de la Selva Central Juan Santos Atahualpa, La Merced T-1-123, Chanchamayo, Peru
1 shared publication Allal Boutajangout
Center for Cognitive Neurology, Department of Neurology, NYU Grossman School of Medicine
1 shared publication
Latest Publications
- Open Access
- 12 December 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 109 (2) , 733-746
Subjective memory complaints in Latin American older adults: Prevalence and risk factors
Background: Subjective memory complaints (SMC) are linked to an increased risk of neurocognitive disorders (NCD). Objective: To estimate the prevalence of SMC and their association with sociodemographic and clinical factors in 3285 older adults (OA) from ten Latin American and Caribbean (LAC) countries. Method: This population-based analysis used secondary data from an international multicenter study on NCD prevalence during the COVID-19 pandemic. Cognitively healthy participants were identified based on clinical criteria, cognitive assessments, and expert consensus. Participants were categorized as with (WSMC; n = 602) or without SMC (NSMC; n = 2683). Sociodemographic and clinical variables were recorded. Cognitive performance was assessed using the Montreal Cognitive Assessment–Short Version (MoCA-T), depressive symptoms with the 15-item Geriatric Depression Scale (GDS-15), and functional decline with the Eight-Item Informant Interview (AD8). Mean difference analyses and logistic regressions were performed. Results: The regional prevalence of SMC was 18.33%, ranging from 11.59% in Guatemala to 26.30% in Peru. OA with SMC showed lower education, poorer cognitive performance, and higher rates of anxiety, falls, and fractures. Regression models revealed significant associations between SMC and lower education (p < 0.001), emotional distress (p < 0.001), age (p = 0.024), anxiety (p = 0.017), infrequent and occasional falls (p = 0.017; p = 0.002), and fractures (p = 0.028). Conclusions: SMC are prevalent among LAC older adults and are associated with multiple risk factors, highlighting their public health relevance and potential as early indicators of NCD risk.
- 12 December 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 109 (2) , 733-746
Open AccessSubjective memory complaints in Latin American older adults: Prevalence and risk factors
Background: Subjective memory complaints (SMC) are linked to an increased risk of neurocognitive disorders (NCD). Objective: To estimate the prevalence of SMC and their association with sociodemographic and clinical factors in 3285 older adults (OA) from ten Latin American and Caribbean (LAC) countries. Method: This population-based analysis used secondary data from an international multicenter study on NCD prevalence during the COVID-19 pandemic. Cognitively healthy participants were identified based on clinical criteria, cognitive assessments, and expert consensus. Participants were categorized as with (WSMC; n = 602) or without SMC (NSMC; n = 2683). Sociodemographic and clinical variables were recorded. Cognitive performance was assessed using the Montreal Cognitive Assessment–Short Version (MoCA-T), depressive symptoms with the 15-item Geriatric Depression Scale (GDS-15), and functional decline with the Eight-Item Informant Interview (AD8). Mean difference analyses and logistic regressions were performed. Results: The regional prevalence of SMC was 18.33%, ranging from 11.59% in Guatemala to 26.30% in Peru. OA with SMC showed lower education, poorer cognitive performance, and higher rates of anxiety, falls, and fractures. Regression models revealed significant associations between SMC and lower education (p < 0.001), emotional distress (p < 0.001), age (p = 0.024), anxiety (p = 0.017), infrequent and occasional falls (p = 0.017; p = 0.002), and fractures (p = 0.028). Conclusions: SMC are prevalent among LAC older adults and are associated with multiple risk factors, highlighting their public health relevance and potential as early indicators of NCD risk.
- 1 April 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 105 (3) , 740-744
The association between measures of sleepiness and subjective cognitive decline symptoms in a diverse population of cognitively normal older adults
Subjective cognitive decline (SCD) is associated with preclinical Alzheimer's disease (AD). Suboptimal sleep is also a risk factor for cognitive decline, but with unclear relationship to SCD. We conducted a retrospective cross-sectional study in a biracial research cohort of 148 cognitively normal older adults who underwent quantification of SCD (Cognitive Change Index; CCI), sleepiness (Epworth Sleepiness Scale; ESS), depression (Geriatric Depression Scale; GDS), and amyloid/tau PET. ESS score was associated with total, amnestic, and non-amnestic CCI scores, after adjustment for GDS, amyloid/tau burden, and race. This supports future longitudinal work on how sleepiness impacts SCD outcomes.
- 1 April 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 105 (3) , 740-744
The association between measures of sleepiness and subjective cognitive decline symptoms in a diverse population of cognitively normal older adults
Subjective cognitive decline (SCD) is associated with preclinical Alzheimer's disease (AD). Suboptimal sleep is also a risk factor for cognitive decline, but with unclear relationship to SCD. We conducted a retrospective cross-sectional study in a biracial research cohort of 148 cognitively normal older adults who underwent quantification of SCD (Cognitive Change Index; CCI), sleepiness (Epworth Sleepiness Scale; ESS), depression (Geriatric Depression Scale; GDS), and amyloid/tau PET. ESS score was associated with total, amnestic, and non-amnestic CCI scores, after adjustment for GDS, amyloid/tau burden, and race. This supports future longitudinal work on how sleepiness impacts SCD outcomes.
- 23 July 2024
- Published by SAGE Publications in Journal of Geriatric Psychiatry and Neurology
- Vol. 38 (1) , 23-31
Two-Year Longitudinal Outcomes of Subjective Cognitive Decline in Hispanics Compared to Non-hispanic Whites
Background: Subjective cognitive decline (SCD), considered a preclinical dementia stage, is less understood in Hispanics, a high-risk group for dementia. We investigated SCD to mild cognitive impairment (MCI) progression risk, as well as baseline and longitudinal features of depressive symptoms, SCD complaints, and objective cognitive performance among Hispanics compared to non-Hispanic Whites (NHW). Methods: Hispanic (n = 23) and NHW (n = 165) SCD participants were evaluated at baseline and 2-year follow-up. Evaluations assessed function, depressive symptoms, SCD, and objective cognitive performance. Results: Hispanics were at increased risk of progression to MCI (OR: 6.10, 95% CI 1.09-34.20, P = .040). Hispanic participants endorsed more depressive symptoms at baseline ( P = .048) that worsened more longitudinally (OR: 3.16, 95% CI 1.18-8.51, P = .023). Hispanic participants had increased SCD complaints on the Brief Cognitive Rating Scale (BCRS) (β = .40 SE: .17, P = .023), and in specific BCRS domains: concentration (β = .13, SE: .07, P = .047), past memory (β = .13, SE: .06, P = .039) and functional abilities (β = .10, SE: .05, P = .037). In objective cognitive performance, Hispanic ethnicity associated with decline in MMSE (β = −.27, SE: .13, P = .039), MoCA (β = −.80 SE: .34, P = .032), Trails A (β = 2.75, SE: .89, P = .002), Trails B (β = 9.18, SE: 2.71, P = .001) and Guild Paragraph Recall Delayed (β = −.80 SE: .28, P = .005). Conclusions: Hispanic ethnicity associated with a significantly increased risk of 2-year progression of SCD to MCI compared to NHW. This increased risk associated with increased depressive symptoms, distinctive SCD features, and elevated amnestic and non-amnestic objective cognitive decline. This supports further research to refine the assessment of preclinical dementia in this high-risk group.
- 23 July 2024
- Published by SAGE Publications in Journal of Geriatric Psychiatry and Neurology
- Vol. 38 (1) , 23-31
Two-Year Longitudinal Outcomes of Subjective Cognitive Decline in Hispanics Compared to Non-hispanic Whites
Background: Subjective cognitive decline (SCD), considered a preclinical dementia stage, is less understood in Hispanics, a high-risk group for dementia. We investigated SCD to mild cognitive impairment (MCI) progression risk, as well as baseline and longitudinal features of depressive symptoms, SCD complaints, and objective cognitive performance among Hispanics compared to non-Hispanic Whites (NHW). Methods: Hispanic (n = 23) and NHW (n = 165) SCD participants were evaluated at baseline and 2-year follow-up. Evaluations assessed function, depressive symptoms, SCD, and objective cognitive performance. Results: Hispanics were at increased risk of progression to MCI (OR: 6.10, 95% CI 1.09-34.20, P = .040). Hispanic participants endorsed more depressive symptoms at baseline ( P = .048) that worsened more longitudinally (OR: 3.16, 95% CI 1.18-8.51, P = .023). Hispanic participants had increased SCD complaints on the Brief Cognitive Rating Scale (BCRS) (β = .40 SE: .17, P = .023), and in specific BCRS domains: concentration (β = .13, SE: .07, P = .047), past memory (β = .13, SE: .06, P = .039) and functional abilities (β = .10, SE: .05, P = .037). In objective cognitive performance, Hispanic ethnicity associated with decline in MMSE (β = −.27, SE: .13, P = .039), MoCA (β = −.80 SE: .34, P = .032), Trails A (β = 2.75, SE: .89, P = .002), Trails B (β = 9.18, SE: 2.71, P = .001) and Guild Paragraph Recall Delayed (β = −.80 SE: .28, P = .005). Conclusions: Hispanic ethnicity associated with a significantly increased risk of 2-year progression of SCD to MCI compared to NHW. This increased risk associated with increased depressive symptoms, distinctive SCD features, and elevated amnestic and non-amnestic objective cognitive decline. This supports further research to refine the assessment of preclinical dementia in this high-risk group.
- Open Access
The relationship between anxiety and levels of Alzheimer’s disease plasma biomarkers
Anxiety is highly prevalent in Alzheimer’s disease (AD), correlating with CSF/PET biomarkers and disease progression. Relationships to plasma biomarkers are unclear. Herein, we compare levels of plasma biomarkers in research participants with and without anxiety at cognitively normal, mild cognitive impairment, and AD dementia stages. We observed significantly higher plasma tau/Aβ42 ratio in AD participants with anxiety versus those without, but did not observe differences at other stages or plasma biomarkers. No such relationships were evident with depression. These results support a unique pathophysiological relationship between anxiety and AD that can be reflected in plasma biomarkers, suggestive of heightened neurodegeneration.
Open AccessThe relationship between anxiety and levels of Alzheimer’s disease plasma biomarkers
Anxiety is highly prevalent in Alzheimer’s disease (AD), correlating with CSF/PET biomarkers and disease progression. Relationships to plasma biomarkers are unclear. Herein, we compare levels of plasma biomarkers in research participants with and without anxiety at cognitively normal, mild cognitive impairment, and AD dementia stages. We observed significantly higher plasma tau/Aβ42 ratio in AD participants with anxiety versus those without, but did not observe differences at other stages or plasma biomarkers. No such relationships were evident with depression. These results support a unique pathophysiological relationship between anxiety and AD that can be reflected in plasma biomarkers, suggestive of heightened neurodegeneration.